Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Research and Markets has announced the addition of the "The Neurodiagnostics Report 2010: Brain Imaging, Biomarkers and NeuroInformatics" report to their offering.

Fully updated second annual industry insider report detailing markets and emerging diagnostics in neurology and psychiatry.

Nearly 2 billion people worldwide and 100 million people in the US are affected by a brain or nervous system disorder including addiction, Alzheimers disease, depression, anxiety, schizophrenia, attention disorders, epilepsy, Parkinsons disease, sensory disorders, and sleep disorders. Diagnosis of these disorders is rapidly changing as new tools are developed for more objective and personalized assessment and treatment.

In addition to the massive unmet markets, long-term growth in neurodiagnostics is being driven by technology advances and equipment upgrades in neuroimaging; new biomarkers and imaging protocols for early diagnosis and disease monitoring; and increased use of imaging and informatics in drug and device development.

NeuroInsights has identified three primary markets in neurodiagnostics which are discussed in detail in this report:

• Neuroimaging: Medical equipment and reagents for research, diagnostics and patient monitoring, including MRI, CT, PET, SPECT, EEG and MEG.

• In vitro diagnostics: Genetic testing, biomarker assays and chemical profiling of human samples, including urine, blood, cerebral spinal fluid and tissue.

• Neuroinformatics: Multidimensional databases and software systems that store and analyze data from the genetic to the behavioral level.

Source: Research and Markets

Discuss more about Radiology in the Radiology user group.